Lucis Secures $20M to Scale AI Healthcare Platform
Lucis, an AI-driven preventive health platform, raised $20 million in Series A funding led by Singular VC and backed by Y Combinator, General Catalyst, and notable angels to expand its data-driven early detection system. The startup claims 75% of users improved at least three biomarkers after six months of following AI-generated health protocols, targeting chronic diseases like diabetes and heart disease across Europe.
Lucis, a Y Combinator-backed AI healthcare startup, secured $20 million in Series A funding four months after its $8.5 million seed round, bringing its total capitalization to $28 million. The round was led by European venture firm Singular and included investors like General Catalyst, Y Combinator, and angels Céline Lazorthes and Manu Lecomte. Founded in 2025 by Maxime Berthelot and Baptiste Debever, Lucis integrates lab data from over 450 European facilities—including Eurofins and Randox—to analyze 110+ biomarkers across metabolism, cardiovascular health, hormones, and other systems. The platform’s AI companion app processes lab results alongside wearable tracker data, lifestyle history, and medical records to generate personalized daily recommendations for nutrition, supplementation, sleep, and exercise. These suggestions are reviewed by a network of physicians to ensure clinical accuracy before being delivered to users. Lucis aims to shift healthcare from reactive treatment to proactive prevention, addressing fragmentation in diagnostic testing. Early results show promise: 99.9% of users had at least one biomarker outside optimal ranges at baseline, but 75% of those who followed the AI’s protocols for six months improved three or more biomarkers organically, without prescription medications. The company cites WHO data indicating 1.8 million avoidable deaths annually in Europe from chronic diseases like diabetes and heart disease, which it claims could be reduced by early intervention. Since launching, Lucis has grown to over 10,000 active users across France, the UK, Ireland, and Portugal, conducting more than one million biomarker analyses. The startup’s rapid scaling reflects investor confidence in AI-driven preventive care, positioning it as a key player in transforming Europe’s healthcare landscape.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.